Question · asked by 1 review
Ataluren vs placebo: Quality of life: CFQ‐R respiratory domain: absolute change from baseline
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Ataluren vs placebo Health‐related quality of life: mean change from baseline in CFQ‐R respiratory domain score Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults and children with CF with at least one class I mutation (PTC) Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for… (2023) · Cochrane Headline outcomes only | no estimate extracted | 2 studies · 506 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.